Alice Rogier

Hello! I am Alice Rogier, a postdoctoral researcher at the Instituto de Tecnología para la Innovación en Salud y Bienestar, ITiSB at Viña del Mar (Chile). I am working on a project funded by CECAN, Centro para prevención y Control del Cáncer to extract information from medical data, in collaboration with the Clínica Las Condes.

During my doctoral research, I specialized in extracting and predicting chemotherapy responses from Electronic Health Records (EHRs). My work focused on mining the vast and diverse data provided by today’s clinical data warehouses to better understand and predict patient reactions to chemotherapy treatments. This involved transforming routine medical data—such as narrative reports, laboratory results, and software records—into structured knowledge that can guide treatment decisions.

I have made two contributions to the field:

I developed graph representations, ChemoOnto (and its reuse) and OntoTox, which organize and integrate knowledge about chemotherapies and their responses, making this information more accessible and useful for research.
I developed ProtoDrift metric, which measures chemotherapy adherence more accurately than traditional methods by accounting for deviations in treatment schedules and dosages. This metric has been validated through survival analysis on a pan-cancer study, with results available at ProtoDrift website. The preprint of this work is available here.

Thank you for visiting my site, where I share updates on my research and explorations at the intersection of data science and healthcare.

news

Apr 01, 2026	I finally obtained a short-term visa 🔖 to officially start as a post-doctoral researcher within the ITiSB, Andrés Bello University. Vamos!
Jan 10, 2026	Building upon recent encounters and discussions, I am currently writing 📝 a new project “CONTICOG: Seguimiento longitudinal del deterioro cognitivo relacionado con la quimioterapia mediante datos digitales centrados en el paciente”, to initiate a collaboration between ITiSB and the Faculty of Rehabilitation Science, and in particular with Falonn Contreras-Osorio and Karol Ramírez-Paradal. The goal of this project is to develop a tool and implement it to measure cognitive impairments 🧠 during the chemotherapy treatment 💊. In parallel, I will further develop ontological tools to represent chemotherapy building upon my PhD work. After cancer diagnosis, the longitudinal cognitive impairment of patients will be measured using a specifically designed cognitive assessment integrated within the +Contigo application. The continuous measure of CRCI with respect to the chemotherapy treatment will allow the exploration of CRCI with other factors such as drug dosage, fatigue or physical exercise ©A. Rogier.
Oct 01, 2025	I recently arrived in Chile 🇨🇱 as a post-doctoral researcher to initiate a collaboration with the Instituto de Tecnología para la Innovación en Salud y Bienestar (ITiSB), an institute of the Andrés Bello University 🏫. It was the opportunity to present to the institute my PhD work as well as a post-doctoral project and possible collaborations 🤝.

selected publications

medRxiv

ProtoDrift: Evaluating the Impact of Small-to-Big Adjustments to Chemotherapy Protocols

Alice Rogier, Elisabeth Ashton, Corine Barat, and 8 more authors

medRxiv, 2025

Preprint available at medRxiv:2025.05.09.25327311

Abs DOI HTML PDF

Adjustments to chemotherapy protocols are common to adapt treatments to individual patient needs, yet consensus on the impact of such adjustements is lacking. We introduce ProtoDrift, a novel metric that quantifies time and dose adjustments in chemotherapies. This weighted distance enables an assessment of their impact on patient outcomes, offering more detailed analyses than the traditional Relative Dose Intensity (RDI). We compared ProtoDrift and RDI prediction performances through survival analyses on 20,808 patients across 38 groups, categorised by cancer location and treatment line at two hospitals. Without optimisation, ProtoDrift achieves either comparable or better prediction results in 71% of patient groups (27 out of 38). Once optimised, ProtoDrift surpasses the RDI C-index predictions in 89% (16 out of 18) of patient groups from the first hospital. This study confirms ProtoDrift as an advanced tool for refining chemotherapy regimen design, highlighting the critical role of time adjustments in patient outcomes.
IOS Press

Using an Ontological Representation of Chemotherapy Toxicities for Guiding Information Extraction and Integration from EHRs

Alice Rogier, Adrien Coulet, and Bastien Rance

Studies in health technology and informatics, 2022

Abs DOI HTML PDF

Introduction: Chemotherapies against cancers are often interrupted due to severe drug toxicities, reducing treatment opportunities. For this reason, the detection of toxicities and their severity from EHRs is of importance for many downstream applications. However toxicity information is dispersed in various sources in the EHRs, making its extraction challenging. Methods: We introduce OntoTox, an ontology designed to represent chemotherapy toxicities, its attributes and provenance. We illustrated the interest of OntoTox by integrating toxicities and grading information extracted from three heterogeneous sources: EHR questionnaires, semi-structured tables, and free-text. Results: We instantiated 53,510, 2,366 and 54,420 toxicities from questionnaires, tables and free-text respectively, and compared the complementarity and redundancy of the three sources. Discussion: We illustrated with this preliminary study the potential of OntoTox to guide the integration of multiple sources, and identified that the three sources are only moderately overlapping, stressing the need for a common representation.